Contact
Please use this form to send email to PR contact of this press release:
Accelerated Approval to Treat Bipolar Depression & Akathisia Could Yield Over $150 in Revenue Per Share; (Nasdaq: NRXP)
TO:
Matthew Duffy, Chief Business Officer
NRx Pharmaceuticals, Inc.
+1 484-254-6134